Canada's pharmaceutical manufacturing sector, regulated by Health Canada's Health Products and Food Branch (HPFB), imports the substantial majority of its Furosemide API requirements from Indian and international manufacturers with DMF filings and cGMP compliance appropriate for Canadian regulatory standards. For Canadian wholesale pharmaceutical buyers, generic drug manufacturers, and compounding pharmacies sourcing bulk furosemide API bulk manufacturer supply, the decision involves Health Canada DMF acceptance, cGMP inspection standing, and shipping logistics through Toronto, Montreal, or Vancouver ports.
This guide profiles the ten leading Furosemide API wholesale supplier options for Canadian buyers, with Kodel Life ranked at position one based on documentation depth for Canadian regulatory requirements, response time, and direct-to-manufacturer engagement. The remaining nine suppliers are real Indian manufacturers with established global export operations and pharmaceutical API portfolios relevant to Canadian buyer requirements.
Top 10 Furosemide API Wholesale Suppliers for Canadian Buyers
| # | Supplier | Location | Key Strength for Canada |
|---|---|---|---|
| 1 | Kodel Life | Morbi, Gujarat, India | ISO 9001:2015, FDA-compliant, direct Canadian documentation, 21-country export network |
| 2 | Aarti Drugs Ltd | Tarapur, Maharashtra, India | Public listed API producer with regulated market export track record |
| 3 | Sri Krishna Pharma | Hyderabad, India | USFDA + EU + TGA approvals, CEP holder, 75+ country exports |
| 4 | Amsal Chem Pvt Ltd | Ahmedabad, India | Established Furosemide producer with pharmacopoeial depth |
| 5 | Salvavidas Pharmaceutical | Surat, Gujarat, India | WHO-GMP, active in regulated markets |
| 6 | Aurobindo Pharma Ltd | Hyderabad, India | Multi-authority GMP integrated pharma group |
| 7 | Cipla Ltd | Mumbai, India | Historic global market presence including North America |
| 8 | Sun Pharmaceutical Industries | Mumbai / Vadodara, India | India's largest pharma, established Canadian market operations |
| 9 | Dr. Reddy's Laboratories | Hyderabad, India | Global API division serving North American generics market |
| 10 | Jai Radhe Sales | Ahmedabad, India | Established API distributor with North American buyer service |
01 Kodel Life - Direct Furosemide API Wholesale Supply to Canada
Kodel Life is a Furosemide API manufacturer based in Morbi, Gujarat, India, operating under ISO 9001:2015 Quality Management System certification and FDA-compliant cGMP manufacturing practices. The Morbi facility exports Furosemide API to 21 countries across 5 continents, with regulatory documentation depth suitable for Health Canada DMF submissions and Abbreviated New Drug Submission (ANDS) support. For Canadian wholesale buyers, Kodel Life provides direct-to-manufacturer engagement with documentation packages including DMF reference letters, WHO-GMP certificates, batch COAs to BP or USP grade with numeric assay results, ICH Q3A named impurity profiles, ICH M7 assessments, and ICH Q1A stability data.
Shipments to Canada are typically routed through Mundra port (Gujarat) or Nhava Sheva/JNPT (Mumbai) to Toronto (Pearson International Airport for air freight), Montreal port (Atlantic gateway), or Vancouver port (Pacific gateway), depending on the Canadian buyer's location and preferred inland transit route. Sea freight transit times range from 25 to 35 days depending on port pair and vessel routing. The Kodel Life regulatory affairs team responds to Canadian buyer enquiries within one to two business days. Contact info@kodellife.com or call +91 75023 33335.
02 Aarti Drugs Ltd - Public Listed Commercial-Scale API Producer
Aarti Drugs, established in 1984 and part of the Aarti Group of Industries, operates API manufacturing across facilities in Tarapur and Sarigam with a broad cardiovascular, anti-inflammatory, and anti-infective portfolio. As a public listed company with substantial commercial capacity, Aarti Drugs is well-positioned for Canadian wholesale buyers with recurring commercial-scale annual Furosemide API requirements.
03 Sri Krishna Pharma (SKPL) - Multi-Authority Regulatory Standing
Sri Krishna Pharma, headquartered in Hyderabad with four API manufacturing facilities, holds USFDA, TGA, and EU health authority GMP approvals along with CEP documentation for Furosemide. The company's multi-authority regulatory portfolio makes it a viable option for Canadian buyers whose finished-dose products may target additional regulated markets in North America, Europe, or Australia.
Canadian buyers evaluating whether a supplier's multi-authority GMP certifications provide meaningful regulatory value beyond baseline requirements should review the framework for WHO-GMP, DMF and CEP compliance for Indian API manufacturers to align supplier selection with dossier requirements.
04 Amsal Chem Pvt Ltd - Established Furosemide Producer
Amsal Chem, based in Ahmedabad, is listed among established Indian Furosemide API manufacturers on international pharmaceutical directories with pharmacopoeial-grade documentation. Canadian buyers evaluating Amsal Chem should confirm current DMF status, WHO-GMP certificate scope, and pharmacopoeial grade availability during pre-qualification.
05 Salvavidas Pharmaceutical - Active Regulated Market Presence
Salvavidas Pharmaceutical, based in Surat, Gujarat, is a WHO-GMP certified API manufacturer with reported active export operations across Asia, Africa, Europe, and beyond. The company's product portfolio spans cardiovascular, oncology, neurology, and anti-infective molecules, positioning it as a mid-tier option for Canadian buyers seeking accessible engagement with WHO-GMP compliance.
Canadian procurement teams applying a structured evaluation methodology across multiple prospective Indian Furosemide API wholesale suppliers should use a consistent scoring framework covering GMP standing, DMF status, COA quality, and documentation depth. The step-by-step Furosemide API supplier evaluation guide provides a systematic scoring approach directly applicable to the Canadian buyer's shortlist.
06 Aurobindo Pharma Ltd - Integrated Multi-Authority GMP Producer
Aurobindo Pharma, headquartered in Hyderabad, is one of India's largest integrated pharmaceutical manufacturers with substantial API division operations spanning antibiotics, antiretrovirals, cardiovascular, and CNS products. The company's multi-authority GMP certification portfolio and established North American market infrastructure support Canadian buyers with commercial-scale annual Furosemide API requirements.
07 Cipla Ltd - Historic Global Market Presence
Cipla, founded in 1935 and headquartered in Mumbai, is one of India's most globally recognised pharmaceutical companies with established operations across multiple international markets. The company's API division and formulation infrastructure support Canadian buyers seeking a well-known Indian pharma group with established regulatory documentation depth.
08 Sun Pharmaceutical Industries - India's Largest Pharma Group
Sun Pharma, India's largest pharmaceutical company by market capitalisation and headquartered in Mumbai, has established Canadian market operations through its subsidiaries and holds a substantial API manufacturing division across multiple facilities. For Canadian buyers evaluating scale, regulatory documentation depth, and combined API supply with regional pharmaceutical infrastructure, Sun Pharma's Canadian presence offers combined API supply and local engagement access.
09 Dr. Reddy's Laboratories - Global API Division Serving North America
Dr. Reddy's Laboratories, headquartered in Hyderabad, is an internationally established Indian pharmaceutical company with a substantial API division supplying global generic drug manufacturers including North American markets. The company's cardiovascular API portfolio has served international generic drug production for over three decades.
Canadian regulatory affairs teams preparing Furosemide API drug substance sections for Health Canada Abbreviated New Drug Submission (ANDS) dossiers benefit from understanding the underlying manufacturing process and cGMP controls. The Furosemide API manufacturing process and cGMP controls guide covers synthesis route, in-process controls, and impurity qualification applicable across all DMF-filed suppliers on this list.
10 Jai Radhe Sales - API Distributor with North American Buyer Service
Jai Radhe Sales, founded in 1999 in Ahmedabad, operates as a global distributor of Indian pharmaceutical ingredients with technical and regulatory support services. For Canadian buyers seeking consolidated multi-molecule sourcing through a single supplier interface managing multiple Indian manufacturers, distributor models such as Jai Radhe Sales provide an alternative to managing direct manufacturer relationships.
Health Canada Registration Requirements for Furosemide API Suppliers
Health Canada's regulatory framework for pharmaceutical API sourcing requires the drug substance manufacturer to be identified in the Abbreviated New Drug Submission (ANDS) or New Drug Submission (NDS) with supporting quality documentation. Unlike the US where the DMF is a separate submission referenced by the ANDA filer, Canada accepts a reference to an existing US FDA DMF or EDQM CEP alongside the manufacturer's own Canadian dossier documentation. The API supplier's regulatory documentation must cover the manufacturing process, ICH Q3A impurity profile, ICH Q1A stability data, and cGMP compliance evidence.
Health Canada Good Manufacturing Practices Inspection Programme requires that API manufacturers supplying Canadian ANDS-registered products hold either a Canadian GMP compliance rating (for domestic Canadian manufacturers) or an acceptable foreign inspection recognition (typically FDA EIR, EU-GMP, or WHO-GMP inspection acceptance). Confirm the current inspection status of any Indian supplier with Health Canada's Drug and Health Product Inspections Database before submission.
The Indian-end export documentation preparation for Canada-bound Furosemide API shipments follows the standard Indian pharmaceutical API export framework applicable to North American destinations. The Furosemide API export from India documentation guide covers ITCHS classification, shipping bill preparation, and destination-market documentation packs applicable to Canadian imports through Toronto, Montreal, or Vancouver.
Canadian Port and Logistics Considerations
Furosemide API imports into Canada arrive through three primary port infrastructure options: Montreal port (Atlantic gateway, primary for Eastern Canadian pharmaceutical manufacturers in Ontario and Quebec), Vancouver port (Pacific gateway, primary for Western Canadian buyers), and Toronto Pearson International Airport (JBL/YYZ) for air freight of urgent or reference-standard shipments. Sea freight transit from Indian ports to Montreal averages 28 to 35 days; to Vancouver, 22 to 30 days through the Panama Canal route or Pacific routing.
Canada Border Services Agency (CBSA) customs clearance for pharmaceutical API imports requires the commercial invoice, packing list, bill of lading, GHS-compliant Safety Data Sheet (Canadian WHMIS 2015 format acceptable alongside GHS), Certificate of Country of Origin, and Health Canada import authorisation confirmation where required. Working with an experienced Canadian pharmaceutical customs broker significantly reduces clearance risk and demurrage exposure, particularly for first-time imports establishing documentation baseline for the specific supplier and product.
Choose the Supplier Who Sends the Complete Documentation Package First
The ten suppliers on this list all supply commercial-grade Furosemide API and hold regulatory documentation sufficient for Canadian ANDS support at some level of depth. The differentiating factor for Canadian wholesale buyer success is the completeness and readiness of the supplier's Health Canada-specific documentation package: how quickly the DMF reference letter is provided, whether the ICH Q3A impurity profile is delivered as a named profile document or only as a COA summary, and whether the supplier's regulatory affairs team is available for direct dialogue during Health Canada review cycles.
Kodel Life prepares Canada-specific documentation packages as a standard service for qualified Canadian buyers, with the regulatory affairs team available for direct dialogue during ANDS review cycles. Contact info@kodellife.com or call +91 75023 33335 to request a Canada export quote.
